| Literature DB >> 29330683 |
Ferran Roche-Campo1,2, Alexandre Bedet3,4, Emmanuel Vivier1,5, Laurent Brochard1,6,7, Armand Mekontso Dessap1,8.
Abstract
BACKGROUND: Cardiac dysfunction is a common cause of weaning failure. Weaning shares some similarities with a cardiac stress test and may challenge active phases of the cardiac cycle-like ventricular contractility and relaxation. This study aimed at assessing systolic and diastolic function during the weaning process and scrutinizing their dynamics during weaning trials.Entities:
Keywords: Diastolic function; Diastolic reserve; Relaxation; Weaning
Year: 2018 PMID: 29330683 PMCID: PMC5768586 DOI: 10.1186/s13613-017-0348-4
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Study flow chart. BMW B-type natriuretic peptide for the fluid management of weaning
Patient characteristics and echocardiographic variables just before the weaning process, according to weaning category (n = 67)
| All patients | Weaning |
| ||
|---|---|---|---|---|
| Short | Prolonged | |||
|
| ||||
| Age, year | 64 (47–76) | 61 (49–75) | 69 (44–81) | 0.50 |
| Male sex | 44 (66) | 31 (63) | 13 (72) | 0.49 |
| SAPS II at ICU admission | 46 (34–53) | 44 (34–58) | 46 (34–50) | 0.50 |
|
| ||||
| Hypertension | 33 (49) | 23 (47) | 10 (56) | 0.52 |
| Diabetes | 17 (26) | 9 (19) | 8 (44) | 0.05 |
| Chronic obstructive pulmonary disease | 17 (25) | 13 (27) | 4 (22) | > 0.99 |
| History of ischemic heart disease | 13 (19) | 11 (22) | 2 (11) | 0.48 |
| Atrial fibrillation | 22 (33) | 13 (27) | 9 (50) | 0.07 |
|
| 0.67 | |||
| Coma | 13 (19) | 9 (18) | 4 (22) | |
| Septic shock | 8 (12) | 5 (10) | 3 (17) | |
| Cardiogenic pulmonary edema | 17 (25) | 14 (29) | 3 (17) | |
| Pneumonia | 18 (27) | 12 (25) | 6 (33) | |
| Cardiac arrest | 4 (6) | 4 (8) | 0 (0) | |
| Surgery | 7 (10) | 5 (10) | 2 (11) | |
|
| ||||
| Septic shock | 33 (49) | 25 (51) | 8 (44) | 0.63 |
| Ventilator-associated pneumonia | 15 (22) | 9 (18) | 6 (33) | 0.21 |
| Acute respiratory distress syndrome | 26 (39) | 18 (37) | 8 (44) | 0.56 |
| Use of neuromuscular blockers | 11 (16) | 9 (18) | 2 (11) | 0.71 |
| Cumulative fluid balance before inclusion, mL | 4322 (949–7898) | 4322 (175–7253) | 4228 (1757–17,957) | 0.27 |
| Duration of invasive MV before inclusion, days | 3 (2–6) | 3 (2–6) | 5 (3–13) | 0.08 |
|
| ||||
| SOFA score | 4 (3–6) | 4 (3–6) | 5 (4–6) | 0.25 |
| Systolic arterial pressure, mmHg | 129 (122–144) | 132 (113–146) | 127 (108–136) | 0.44 |
| Heart rate, beats/min | 93 (82–105) | 93 (83–106) | 91 (79–104) | 0.60 |
| Respiratory rate, beats/min | 25 (19–30) | 23 (18–29) | 29 (27–33) | 0.06 |
| RPP, beats/min·mmHg | 12,500 (11,288–15,346) | 12,576 (10,744–15,520) | 12,423 (12,245–13,035) | > 0.99 |
| Arterial blood gases | ||||
| pH, units | 7.44 (7.40–7.47) | 7.44 (7.40–7.47) | 7.44 (7.41–7.47) | 0.77 |
| PaO2/FiO2 ratio, mmHg | 210 (182–270) | 222 (188–277) | 186 (153–226) | < 0.01 |
| PaCO2, mmHg | 41 (35–46) | 40 (35–46) | 42 (37–49) | 0.42 |
| BNP, pg/ml | 331 (114–602) | 302 (108–588) | 415 (114–842) | 0.51 |
| Protidemia, g/L | 58 (51–66) | 58 (54–66) | 54 (49–66) | 0.39 |
| Creatinine, micromol/L | 79 (57–101) | 81 (59–98) | 73 (55–107) | 0.96 |
| Randomization in the interventional group | 34 (51) | 25 (51) | 9 (50) | 0.94 |
|
| ||||
| LVEF, % | 55 (40–60) | 50 (37–60) | 60 (50–62) | 0.26 |
| Cardiac index, L/min/m2 | 3.0 (2.2–3.6) | 3.1 (2.3–3.6) | 2.7 (2.1–3.7) | 0.52 |
|
| ||||
| LVEF < 50% | 25 (37) | 21 (43) | 4 (22) | 0.12 |
|
| ||||
| LVEF ≥ 50% and BNP > 35 pg/mL and ( | 11 (17) | 4 (8) | 7 (39) | 0.01 |
| Heart valve diseaseb | 23 (34) | 14 (29) | 9 (50) | 0.10 |
| RV/LV area ratio | 0.6 (0.5–0.7) | 0.6 (0.4–0.7) | 0.6 (0.5–0.7) | 0.67 |
| Tricuspid annular plane systolic excursion, cm | 1.9 (1.5–2.6) | 2.1 (1.7–2.7) | 1.5 (1.3–1.9) | 0.03 |
| Systolic pulmonary artery pressure, mmHg | 38 (25–51) | 37 (25–49) | 46 (25–66) | 0.16 |
SAPS Simplified Acute Physiologic Score, ICU intensive care unit, MV mechanical ventilation, SOFA sequential organ failure assessment, RPP product of heart rate and systolic arterial pressure, FiO fraction of inspired oxygen, BNP B-type natriuretic peptide, LVEF left ventricle ejection fraction, E early diastolic velocity measured using Doppler transmitral flow, A late diastolic velocity measured using Doppler transmitral flow, e′ early peak diastolic velocity of mitral annulus, a′ late peak diastolic velocity of mitral annulus, RV right ventricular end-diastolic area, LV left ventricular end-diastolic area
aDiastolic function could not be assessed in one patient for e′ and in two patients for E/e′ ratio
bHeart valve disease is defined as a severe aortic or mitral regurgitation (grade III/IV). Data are presented as n (%) or median (1st quartile–3rd quartile)
Cardiovascular treatments and outcomes according to weaning category (n = 67)
| All patients | Weaning |
| ||
|---|---|---|---|---|
| Short | Prolonged | |||
|
| ||||
| Diuretics | 56 (84) | 38 (78) | 18 (100) | 0.03 |
| Dobutamine | 19 (28) | 15 (31) | 4 (22) | 0.50 |
| Vasodilator | 30 (45) | 26 (53) | 4 (22) | 0.02 |
| Amiodarone | 19 (28) | 13 (27) | 6 (33) | 0.58 |
| Any cardiovascular treatment | 62 (93) | 44 (90) | 18 (100) | 0.31 |
| Average daily furosemide dose during weaning, mg | 25 (4–59) | 30 (1–59) | 22 (6–56) | 0.94 |
| Average daily fluid balance during weaning, mL | − 757 (− 2016 to − 81) | − 1202 (− 2342 to − 477) | 51 (− 638 to 449) | < 0.01 |
| Average daily urine output during weaning, mL | 2588 (1971 to 3863) | 2950 (2205 to 4167) | 1967 (1649 to 2912) | 0.02 |
|
| ||||
| Time to first successful extubation, days | 2 (1–6) | 1 (1–2) | 13 (10–32) | < 0.01 |
| Ventilator free days at day-28, days | 24 (18–27) | 27 (25–27) | 0 (0–16) | < 0.01 |
| Time to discharge from ICU, days | 9 (5–18) | 7 (4–10) | 31 (15–53) | < 0.01 |
| Time to discharge from hospital, days | 28 (15–53) | 22 (13–32) | 39 (22–53) | 0.07 |
| ICU mortality | 9 (13) | 2 (4) | 7 (39) | < 0.01 |
| Hospital mortality | 10 (15) | 3 (6) | 7 (39) | < 0.01 |
Data are presented as n (%) or median (1st quartile–3rd quartile). Patient who died before day-28 had 0 ventilator free days
ICU intensive care unit
Fig. 2Systolic arterial pressure (a), heart rate (b) and pressure-rate product (c) at the start (white square) and the end (black square) of consecutive weaning trials during the weaning process (n = 31), according to first trial outcome (success or failure). #p value < 0.05 as compared to the start of weaning trial (Wilcoxon test)
Fig. 3Tissue Doppler s′ wave (a), e′ wave (b) and E/e′ ratio (c), recorded with echocardiography at the start (white square) and the end (black square) of consecutive weaning trials during the weaning process (n = 31), according to first trial outcome (success or failure). #p value < 0.05 as compared to the start of weaning trial (Wilcoxon test)
Percent change in echocardiographic variables between the start and the end of the first weaning trial (n = 31), according to outcome (success or failure)
| All | Success | Failure |
| |
|---|---|---|---|---|
| Delta | − 3% (− 12%; 9%) | − 3% (− 7%; 5%) | − 2% (− 15%; 9%) | 0.872 |
| Delta | − 3% (− 12%; − 4%) | 3% (− 9%; 6%) | − 6% (− 18%; − 3%) | 0.02 |
| Delta | 13% (8%; 19%) | 12% (7%; 16%) | 14% (11%; 23%) | 0.20 |
| Delta | 16% (9%; 25%) | 10% (4%; 14%) | 26% (20%; 28%) | < 0.01 |
Data are presented as median (1st quartile; 3rd quartile)
s′ peak systolic velocity at the lateral mitral valve annulus, e′ early peak diastolic velocity of mitral annulus, E early diastolic velocity measured using Doppler transmitral flow
as′ could not be assessed in three patients